AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30908369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 3 × 5 minutes at 220 mm Hg in both arms with 5-minute rests
Number of subjects: 16
Study 30908369 — intervention group
Group type: COMPARATOR
Intervention: Sham Intervention (SHAM) - occlusion pressure set at 10 mm Hg
Number of subjects: 16
Study 30908369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 16
Study 31106659 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid group: 2 omega-3 fatty acid capsules (330 mg each) daily + vitamin D3 placebo weekly
Number of subjects: 81
Study 31106659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acid placebo capsules daily
Number of subjects: 81
Study 31106659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosupplementation group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acids capsules daily for 8 weeks
Number of subjects: 81
Study 31106659 — intervention group
Group type: COMPARATOR
Intervention: Control group: vitamin D3 placebo weekly + omega-3 fatty acid placebo capsules daily
Number of subjects: 81
Study 29494787 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program (n = 42)
Number of subjects: 81
Study 29494787 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 39)
Number of subjects: 81
Study 27751554 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS plus alteplase (0.3 mg or 1.0 mg every 8 hours for up to nine doses)
Number of subjects: 96
Study 27751554 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 96
Study 24851847 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 49
Study 24851847 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 49
Study 24851847 — intervention group
Group type: COMPARATOR
Intervention: Resting Control
Number of subjects: 49
Study 22495940 — intervention group
Group type: EXPERIMENTAL
Intervention: COMET + therapy as usual (TAU)
Number of subjects: 61
Study 22495940 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 61
Study 20374035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola algida mixture consumed for 14 consecutive days after each cycle of chemotherapy
Number of subjects: 130
Study 20374035 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorohexidine mouth wash used every day
Number of subjects: 130
Study 20374035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola algida mixture
Number of subjects: 130
Study 18389895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r)
Number of subjects: 984
Study 18389895 — intervention group
Group type: COMPARATOR
Intervention: Comparator ritonavir‐boosted protease inhibitor (CPI/r)
Number of subjects: 984
Study 16288157 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (45-50 minutes, twice a week for 8 weeks)
Number of subjects: 46
Study 16288157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study 12033654 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (Subutex)
Number of subjects: 106
Study 12033654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 11414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg once daily for 3 days
Number of subjects: 202
Study 11414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day
Number of subjects: 202
Study 11414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg together with azithromycin 50 mg once daily for 3 days
Number of subjects: 202
Study 9339615 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestion via headphones during anaesthetic period
Number of subjects: 50
Study 9339615 — intervention group
Group type: COMPARATOR
Intervention: Blank tape played during anaesthetic period (Control)
Number of subjects: 50
Study 8439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nizatidine (300 mg) with early supper (18.00 hours)
Number of subjects: 11
Study 8439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Late nizatidine (300 mg) with late supper (21.00 hours)
Number of subjects: 11
Study 8439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nizatidine (300 mg) with late supper (21.00 hours)
Number of subjects: 11
Study 8439637 — intervention group
Group type: COMPARATOR
Intervention: Placebo with early supper (18.00 hours)
Number of subjects: 11
Study 8439637 — intervention group
Group type: COMPARATOR
Intervention: Placebo with late supper (21.00 hours)
Number of subjects: 11
Study 3755791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 3755791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 3755791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 3755791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Pirenzepine
Number of subjects: 0
Study 3755791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-uterine devices (IUDs)
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous pregnancy
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude to family planning
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Better knowledge of family planning
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 879
Study 31090059 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 879
Study 29143803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (125 g protein/day) using novel functional foods
Number of subjects: 21
Study 29143803 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (80 g protein/day)
Number of subjects: 21
Study 25351455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-consultation educational group intervention
Number of subjects: 41
Study 25351455 — intervention group
Group type: COMPARATOR
Intervention: Routine education
Number of subjects: 41
Study 23336160 — intervention group
Group type: EXPERIMENTAL
Intervention: INSURE method
Number of subjects: 64
Study 23336160 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 64
Study 22189641 — intervention group
Group type: EXPERIMENTAL
Intervention: GO adhesive system
Number of subjects: 20
Study 22189641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper SE Plus
Number of subjects: 20
Study 22189641 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond All‐In‐One
Number of subjects: 20
Study 22189641 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil 3S Bond
Number of subjects: 20
Study 19702375 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame-of-reference training
Number of subjects: 0
Study 19702375 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 0
Study 16412769 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist plus recombinant luteinizing hormone
Number of subjects: 133
Study 16412769 — intervention group
Group type: COMPARATOR
Intervention: Standard GnRH agonist flare-up protocol
Number of subjects: 133
Study 15520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) combined with mild hypothermia (core temperature of 35 degrees C for 24 hours)
Number of subjects: 49
Study 15520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) combined with mild hypothermia
Number of subjects: 49
Study 15520321 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with mild hypothermia (core temperature of 35 degrees C for 24 hours)
Number of subjects: 49
Study 15520321 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with mild hypothermia
Number of subjects: 49
Study 15520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 49
Study 11417474 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin continuous infusion (CI) 60 mg/m2 days 2-4
Number of subjects: 77
Study 11417474 — intervention group
Group type: COMPARATOR
Intervention: Bolus daunorubicin (30-min infusion) 60 mg/m2
Number of subjects: 77
Study 11417474 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin continuous infusion (CI)
Number of subjects: 77
Study 11417474 — intervention group
Group type: COMPARATOR
Intervention: Bolus daunorubicin (30-min infusion)
Number of subjects: 77
Study 9562303 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-neurofilament (NF) autoantibodies detected by ELISA in ALS patients
Number of subjects: 85
Study 9562303 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study 9562303 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 85
Study 9562303 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-NF antibodies in ALS patients
Number of subjects: 85
Study 8179465 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (given for 2 days)
Number of subjects: 53
Study 8179465 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (long-term treatment for 28 days)
Number of subjects: 53
Study 8179465 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (long-term treatment)
Number of subjects: 53
Study 8179465 — intervention group
Group type: COMPARATOR
Intervention: Control group (36 controls)
Number of subjects: 53
Study 3068741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg three times a day
Number of subjects: 60
Study 3068741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 31732174 — intervention group
Group type: EXPERIMENTAL
Intervention: D + E
Number of subjects: 454
Study 31732174 — intervention group
Group type: EXPERIMENTAL
Intervention: D
Number of subjects: 454
Study 31732174 — intervention group
Group type: EXPERIMENTAL
Intervention: D and D + E
Number of subjects: 454
Study 31732174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss >10%
Number of subjects: 454
Study 29858218 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 22
Study 27908500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Skills Curriculum (MSC) during laparoscopic simulator training
Number of subjects: 60
Study 27908500 — intervention group
Group type: COMPARATOR
Intervention: Control group (FLS training only)
Number of subjects: 60
Study 25913081 — intervention group
Group type: EXPERIMENTAL
Intervention: TruView EVO2
Number of subjects: 78
Study 25913081 — intervention group
Group type: EXPERIMENTAL
Intervention: TruView PCD
Number of subjects: 78
Study 25913081 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Number of subjects: 78
Study 22890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study 22890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 30
Study 22890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 30
Study 22890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 30
Study 21803405 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg delprostenate
Number of subjects: 1131
Study 21803405 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 μg delprostenate
Number of subjects: 1131
Study 21803405 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF(2α) 7 d apart
Number of subjects: 1131
Study 21803405 — intervention group
Group type: COMPARATOR
Intervention: PGF(2α) 8 d apart
Number of subjects: 1131
Study 21803405 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® with TAI at 42 h
Number of subjects: 1131
Study 21803405 — intervention group
Group type: COMPARATOR
Intervention: AI 12 h after estrus detection
Number of subjects: 1131
Study 21803405 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® plus GnRH at TAI
Number of subjects: 1131
Study 21803405 — intervention group
Group type: COMPARATOR
Intervention: AI following detection of spontaneous estrus
Number of subjects: 1131
Study 19339374 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora + tailored newsletter
Number of subjects: 238
Study 19339374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletter only
Number of subjects: 238
Study 19339374 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 238
Study 16513871 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 32
Study 16513871 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2.5 mg)
Number of subjects: 32
Study 16513871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15479359 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone PEG tubes
Number of subjects: 138
Study 15479359 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane PEG tubes
Number of subjects: 138
Study 10857527 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Rating Scale‐Revised (NRS‐R)
Number of subjects: 286
Study 9307345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50-150 mg daily)
Number of subjects: 200
Study 9307345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9307345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 200
Study 8665707 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 59
Study 8665707 — intervention group
Group type: COMPARATOR
Intervention: Regular HME users
Number of subjects: 59
Study 2693118 — intervention group
Group type: EXPERIMENTAL
Intervention: cromakalim (n = 12)
Number of subjects: 18
Study 2693118 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 6)
Number of subjects: 18
Study 334132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 63 mg
Number of subjects: 9
Study 334132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 125 mg
Number of subjects: 9
Study 334132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 9
Study 334132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 9
Study 334132 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide 0 mg (control)
Number of subjects: 9
Study 30946600 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-guided management
Number of subjects: 41
Study 30946600 — intervention group
Group type: COMPARATOR
Intervention: Standard transthoracic echocardiography-guided management
Number of subjects: 41
Study 27417302 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (n=34)
Number of subjects: 73
Study 27417302 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and acceptance and commitment therapy intervention (n=39)
Number of subjects: 73
Study 27417302 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 73
Study 25677598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mm Hg)
Number of subjects: 2839
Study 25677598 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (systolic blood pressure <180 mm Hg)
Number of subjects: 2839
Study 25677598 — intervention group
Group type: EXPERIMENTAL
Intervention: IVH volume
Number of subjects: 2839
Study 25143296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1839
Study 25143296 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1839
Study 25143296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking cessation
Number of subjects: 1839
Study 25143296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking cessation (NRT participants)
Number of subjects: 1839
Study 21993383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 30
Study 19282202 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 79
Study 19282202 — intervention group
Group type: COMPARATOR
Intervention: Control (without GDM)
Number of subjects: 79
Study 19282202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GDM and control groups during head-up tilt (HUT)
Number of subjects: 79
Study 19282202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GDM and control groups during pregnancy
Number of subjects: 79
Study 18251162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (VK2), 45 mg orally every day after therapy for HCC
Number of subjects: 45
Study 18251162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VK2 treatment)
Number of subjects: 45
Study 18251162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (VK2)
Number of subjects: 45
Study 18251162 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin concentration
Number of subjects: 45
Study 15771794 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplatin dosage calculated according to body surface
Number of subjects: 54
Study 15771794 — intervention group
Group type: COMPARATOR
Intervention: Paraplatin dosage calculated according to area under the curve (AUC)
Number of subjects: 54
Study 12201623 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1600
Study 12201623 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study 9883316 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 stimulation
Number of subjects: 26
Study 9883316 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation (5 micrograms/ml)
Number of subjects: 26
Study 9883316 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 26
Study 9883316 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 26
Study 9883316 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV stimulation (640 HU/ml)
Number of subjects: 26
Study 8722434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (< 80 mmol/day)
Number of subjects: 34
Study 8722434 — intervention group
Group type: COMPARATOR
Intervention: High salt diet (120 mmol of sodium chloride per day)
Number of subjects: 34
Study 8722434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 34
Study 8722434 — intervention group
Group type: COMPARATOR
Intervention: High salt diet
Number of subjects: 34
Study 2048708 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (tourniquet applied after midazolam injection)
Number of subjects: 30
Study 2048708 — intervention group
Group type: COMPARATOR
Intervention: Group I (tourniquet applied before midazolam injection)
Number of subjects: 30
Study 2048708 — intervention group
Group type: COMPARATOR
Intervention: Group III (no tourniquet)
Number of subjects: 30
Study 7044525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg p.o. twice daily)
Number of subjects: 117
Study 7044525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (250 mg p.o. 4 times daily) with hydrocortisone (20 mg twice daily)
Number of subjects: 117
Study 7044525 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tamoxifen and aminoglutethimide
Number of subjects: 117
Study 7044525 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 117
Study 7044525 — intervention group
Group type: COMPARATOR
Intervention: Aminoglutethimide
Number of subjects: 117
Study 31670194 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-focused intervention (training in small groups of 3-5 for six weeks, two times per week for 75 minutes)
Number of subjects: 122
Study 31733764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tensioning
Number of subjects: 60
Study 31733764 — intervention group
Group type: COMPARATOR
Intervention: Neural gliding
Number of subjects: 60
Study 28223031 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 141
Study 28223031 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 141
Study 28223031 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 141
Study 25394826 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxygen fraction (FiO₂) 1.0, 0.21, 0.15, and 0.10 with body positions (upright, supine, and 45° head down)
Number of subjects: 11
Study 25394826 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (FiO₂ = 0.10)
Number of subjects: 11
Study 25394826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece used during experimental trials
Number of subjects: 11
Study 23870540 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention website with information about the compensation process and a therapist-assisted problem-solving course
Number of subjects: 176
Study 23870540 — intervention group
Group type: COMPARATOR
Intervention: Control website with links to existing websites
Number of subjects: 176
Study 21490143 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnSuppl group (6 mg Zn added to the supplement dose)
Number of subjects: 137
Study 21490143 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 g dry weight of iron-fortified cereal porridge and a liquid multivitamin supplement without zinc)
Number of subjects: 137
Study 21490143 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnFort group (zinc added to provide 6 mg Zn per 25 g dry weight of porridge and multivitamin without zinc)
Number of subjects: 137
Study 19622294 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus surgery (200 mg twice daily for six days before surgery)
Number of subjects: 59